ALBI Calculator
Estimate the Albumin-Bilirubin (ALBI) score and grade using serum albumin and bilirubin values. This premium calculator is designed for fast clinical reference, education, and liver function stratification support.
Calculate ALBI Score
What Is an ALBI Calculator?
An ALBI calculator estimates the Albumin-Bilirubin score, a validated liver function metric based on two routinely measured laboratory values: serum albumin and total bilirubin. The model was developed to provide a more objective method of assessing hepatic reserve, especially in patients with hepatocellular carcinoma, but it is also widely discussed in broader hepatology workflows. Unlike more complex systems that combine clinical findings such as ascites or encephalopathy with laboratory data, ALBI uses a mathematically derived formula with only biochemical inputs. That simplicity is a major reason clinicians, researchers, and trainees often use an ALBI calculator during chart review, case conferences, and treatment planning discussions.
The formal ALBI equation is:
ALBI score = (log10 bilirubin in µmol/L × 0.66) + (albumin in g/L × -0.085)
After the score is calculated, it is categorized into a grade:
- ALBI Grade 1: score less than or equal to -2.60
- ALBI Grade 2: score greater than -2.60 and less than or equal to -1.39
- ALBI Grade 3: score greater than -1.39
In general terms, a lower ALBI score indicates better preserved liver function. A higher score reflects relatively worse hepatic reserve. Because albumin reflects the liver’s synthetic capacity and bilirubin reflects excretory function, combining these values into a continuous score gives a practical snapshot of liver status.
Why ALBI Matters in Clinical Practice
The ALBI calculator is especially useful in situations where subtle differences in liver function matter. In hepatocellular carcinoma, treatment decisions may depend on whether the liver can tolerate resection, locoregional therapy, systemic treatment, or radiotherapy. A patient may appear stable by broad clinical criteria, yet still have measurable differences in albumin and bilirubin that affect prognosis and treatment tolerance. ALBI helps reveal those differences.
Another strength of ALBI is reproducibility. It avoids subjective interpretation of symptoms or physical findings that can vary among observers. In multidisciplinary settings, that can improve consistency when comparing patients across clinics, centers, or clinical trials. It is not a complete replacement for broader assessment, but it is a highly efficient and standardized tool.
Common Use Cases for an ALBI Calculator
- Baseline liver function assessment in hepatocellular carcinoma.
- Pre-treatment risk discussion before surgery, ablation, embolization, or systemic therapy.
- Monitoring hepatic reserve over time with repeat lab testing.
- Research stratification and retrospective chart review.
- Education for trainees learning modern liver function metrics.
How to Use This ALBI Calculator Correctly
To use the calculator accurately, begin with current laboratory values. Enter albumin in g/L. Enter bilirubin either in µmol/L or mg/dL, depending on how your lab reports results. If you choose mg/dL, this page converts bilirubin to µmol/L using the standard approximation of 1 mg/dL = 17.1 µmol/L. The calculator then applies the ALBI formula, returns the exact score, assigns the grade, and generates a chart comparing your score with the standard ALBI grade cutoffs.
Step-by-Step Input Guidance
- Check that albumin is reported in g/L, not g/dL.
- Verify whether bilirubin is in µmol/L or mg/dL.
- Use total bilirubin unless a specific protocol states otherwise.
- Review whether the labs are current enough for the intended decision.
- Interpret the result together with the full clinical picture.
Understanding the ALBI Formula
ALBI works because it combines two biologically meaningful markers. Albumin falls when the liver’s synthetic function is impaired, while bilirubin rises when excretory handling is reduced or cholestasis is present. The formula weights each value to produce a continuous score. The logarithmic treatment of bilirubin is important because bilirubin values may span a wide range, and a simple linear contribution would not reflect their clinical distribution as effectively.
Because albumin contributes a negative term, higher albumin pushes the ALBI score downward, which is favorable. Because bilirubin contributes a positive term through the logarithmic function, higher bilirubin pushes the ALBI score upward, which is less favorable. The final number is therefore intuitive once you understand the structure: lower is better, higher is worse.
ALBI Grade Interpretation
The three ALBI grades are broad risk strata rather than definitive treatment rules. Grade 1 usually corresponds to the best preserved liver function of the three categories. Grade 2 is intermediate and often includes a diverse group of patients, some of whom may still tolerate substantial therapy depending on the broader clinical context. Grade 3 suggests more advanced impairment and typically prompts additional caution.
| ALBI Grade | Score Range | General Interpretation | Typical Clinical Meaning |
|---|---|---|---|
| Grade 1 | ≤ -2.60 | Best preserved hepatic reserve | Often associated with better tolerance of therapy and improved prognosis compared with higher grades |
| Grade 2 | > -2.60 to ≤ -1.39 | Intermediate liver function | Requires individualized treatment planning and closer monitoring |
| Grade 3 | > -1.39 | More impaired liver function | Often associated with increased treatment risk and poorer overall prognosis |
ALBI Compared with Child-Pugh
One of the most common questions is how ALBI compares with the Child-Pugh classification. Child-Pugh remains widely used and includes bilirubin, albumin, INR, ascites, and encephalopathy. It is clinically valuable, but two of its components, ascites and encephalopathy, can be subjectively assessed and influenced by treatment or observer variability. ALBI removes that subjectivity by relying only on laboratory data.
This does not mean ALBI replaces Child-Pugh in every setting. Instead, many clinicians view ALBI as a complementary tool, especially when they want finer biochemical discrimination inside apparently similar groups. For example, two patients both classified as Child-Pugh A may still have noticeably different ALBI scores and therefore different practical levels of hepatic reserve.
| Feature | ALBI | Child-Pugh |
|---|---|---|
| Number of variables | 2 | 5 |
| Uses subjective clinical findings | No | Yes, ascites and encephalopathy |
| Continuous mathematical score | Yes | No, point-based class system |
| Core laboratory markers | Albumin, bilirubin | Albumin, bilirubin, INR |
| Common role | Objective liver reserve stratification | Broad severity classification in chronic liver disease |
Real Statistics Relevant to ALBI Use
The ALBI model is heavily discussed in hepatocellular carcinoma because HCC is one of the most common primary liver cancers worldwide. According to the National Cancer Institute SEER program, the recent U.S. age-adjusted incidence rate for liver and intrahepatic bile duct cancer has been roughly 9.5 per 100,000 people per year, with a death rate of about 6.0 per 100,000 people per year. While ALBI is not a cancer incidence tool, these figures show why practical liver function stratification matters in oncology and hepatology.
Burden of underlying chronic liver disease is also substantial. The U.S. Centers for Disease Control and Prevention reports that chronic liver disease and cirrhosis remain major causes of mortality in adults, with tens of thousands of deaths annually. In that context, standardized biochemical tools such as ALBI are relevant well beyond research papers.
| Statistic | Recent Figure | Why It Matters for ALBI | Source Type |
|---|---|---|---|
| U.S. liver and intrahepatic bile duct cancer incidence | About 9.5 per 100,000 per year | Shows the clinical scale of diseases in which liver reserve assessment is essential | National Cancer Institute SEER |
| U.S. liver and intrahepatic bile duct cancer mortality | About 6.0 per 100,000 per year | Reinforces the importance of prognosis and treatment selection tools | National Cancer Institute SEER |
| Standard bilirubin conversion | 1 mg/dL = 17.1 µmol/L | Critical for accurate ALBI calculation when using U.S. lab units | Clinical chemistry convention |
| ALBI grade count | 3 grades | Provides simple, standardized interpretation after a continuous score is derived | ALBI model structure |
Limitations of an ALBI Calculator
No liver score should be interpreted in isolation. The ALBI calculator does not capture INR, sodium, creatinine, platelet count, portal hypertension severity, performance status, tumor burden, active infection, or radiographic findings. It also does not directly account for acute events such as biliary obstruction, transient dehydration, active alcohol-associated hepatitis, or recent albumin infusion. If bilirubin is elevated because of a non-hepatic or reversible cause, the ALBI score may appear worse even when long-term hepatic reserve is different.
Similarly, albumin can be influenced by malnutrition, inflammation, nephrotic loss, or fluid shifts. That means ALBI is best viewed as a high-value biochemical lens rather than a complete diagnosis. It is most powerful when interpreted with medical history, examination, imaging, and broader laboratory review.
Situations Requiring Extra Caution
- Acute cholestasis or biliary obstruction
- Recent albumin administration
- Sepsis or severe systemic inflammation
- Mixed hepatic and non-hepatic causes of jaundice
- Lab unit entry errors, especially albumin g/dL versus g/L
Practical Tips for Clinicians and Students
If you use an ALBI calculator routinely, build a habit of checking units first. This is the most common avoidable source of error. Albumin in many U.S. reports may appear as g/dL, but the ALBI formula requires g/L. If albumin is reported as 3.5 g/dL, that corresponds to 35 g/L. Likewise, if bilirubin is in mg/dL, convert it to µmol/L before applying the logarithm. The calculator on this page performs that conversion automatically when you select mg/dL.
It is also helpful to trend ALBI over time rather than relying on a single value. A patient whose score is drifting upward across several visits may be showing clinically meaningful deterioration in hepatic reserve even if the grade has not yet changed. In tumor boards or pre-treatment planning meetings, that trend can be more informative than a one-time number.
Authoritative References and Further Reading
For readers who want higher-quality background information, these authoritative public sources are useful:
- National Cancer Institute SEER: Liver and Intrahepatic Bile Duct Cancer Statistics
- Centers for Disease Control and Prevention: Liver Disease FastStats
- National Library of Medicine Bookshelf: Bilirubin and Liver-Related Clinical Background
Bottom Line
An ALBI calculator is a streamlined way to estimate liver reserve using two objective lab measures: albumin and bilirubin. It is especially valuable in hepatocellular carcinoma and other situations where nuanced hepatic function assessment affects management. The score is easy to compute, easy to trend, and easy to communicate. Still, it should always be used alongside comprehensive clinical judgment. If you are using this result for patient care, confirm units, interpret the value in context, and follow institutional or specialty guidance when treatment decisions are being made.